News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,066 Results
Type
Article (38988)
Company Profile (277)
Press Release (644801)
Section
Business (203838)
Career Advice (1987)
Deals (35358)
Drug Delivery (84)
Drug Development (80773)
Employer Resources (168)
FDA (16085)
Job Trends (14800)
News (344485)
Policy (32431)
Tag
Academia (2530)
Alliances (49041)
Alzheimer's disease (1218)
Approvals (16005)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11489)
Biotechnology (196)
Breast cancer (111)
Cancer (968)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (64000)
Collaboration (339)
Compensation (173)
COVID-19 (2523)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6113)
Earnings (84489)
Employer resources (146)
Events (109115)
Executive appointments (256)
FDA (16550)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4320)
Healthcare (18659)
Infectious disease (2602)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16275)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13153)
Medtech (13158)
Mergers & acquisitions (19120)
Metabolic disorders (375)
Neuroscience (1462)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1304)
Obesity (223)
Opinion (176)
Patents (96)
People (56158)
Phase I (19867)
Phase II (28179)
Phase III (21032)
Pipeline (320)
Postmarket research (2553)
Preclinical (8452)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21460)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3560)
United States (12285)
Vaccines (541)
Weight loss (163)
Date
Today (197)
Last 7 days (1068)
Last 30 days (3241)
Last 365 days (35450)
2024 (31168)
2023 (40076)
2022 (51175)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37048)
Australia (6040)
California (2936)
Canada (1207)
China (224)
Colorado (127)
Connecticut (131)
Europe (79307)
Florida (415)
Georgia (104)
Illinois (320)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2374)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (674)
Northern California (1304)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (404)
Utah (84)
Washington State (335)
684,066 Results for "lunit inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Volpara Health enters agreement to be acquired by Lunit, Inc.
Volpara Health Technologies (“Volpara,” “the Group,” or “the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, is pleased to announce it has entered into an agreement to be acquired by Lunit Inc.
December 13, 2023
·
3 min read
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, proudly announces the successful completion of its acquisition of Volpara Health Technologies, a global leader in medical software for breast cancer screening.
May 22, 2024
·
4 min read
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit’s AI-powered analyzer for quantitative immune phenotyping from H&E.
March 26, 2024
·
5 min read
Lunit’s AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists’ workload while enhancing cancer detection rates.
April 8, 2024
·
3 min read
Genetown
Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings
Boston Imaging announced that Samsung has signed a supply contract with Lunit Inc., a leading provider of artificial intelligence powered solutions for cancer diagnostics and therapeutics, to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
January 25, 2024
·
5 min read
Deals
Update on Lunit’s Acquisition of Volpara: New Zealand High Court Initial Approval Secured
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a significant update on its acquisition of Volpara Health Technologies.
March 13, 2024
·
4 min read
Lunit Secures $150 Million in Capital Increase
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the successful completion of a significant paid-in capital increase of $150 million.
November 15, 2023
·
2 min read
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announces two commercial deals that signal its expansion in Europe.
March 18, 2024
·
3 min read
Policy
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT
Lunit announced that it has received U.S. Food and Drug Administration 510 clearance for its 3D Breast Tomosynthesis AI solution, Lunit INSIGHT DBT.
November 14, 2023
·
3 min read
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification
Lunit today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10.
April 1, 2024
·
6 min read
1 of 68,407
Next
